Industry Overview

India diabetes diagnosis and treatment market was valued at $11.9 billion in 2025 and is projected to reach $26.1 billion by 2035, growing at a CAGR of 8.2% during the forecast period (2026–2035). The market is growing due to the rising prevalence of diabetes across India, particularly driven by the increasing incidence of Type 2 diabetes linked to sedentary lifestyles, urbanization, and dietary shifts. This expanding patient base is strengthening demand for both diagnostic solutions, such as blood glucose monitoring and continuous glucose monitoring, as well as long-term therapeutic interventions, including insulin and oral anti-diabetic drugs. In parallel, improving awareness around early diagnosis and routine monitoring is encouraging higher adoption of screening and management tools, especially in urban and semi-urban populations. The market is also supported by ongoing improvements in healthcare access and the availability of advanced treatment options, which are enabling more consistent disease management.

Market Dynamics

Rising Adoption of Continuous Glucose Monitoring (CGM) Enhancing Diabetes Management Efficiency

The increasing adoption of continuous glucose monitoring systems is emerging as a significant trend in the Indian diabetes diagnosis and treatment market. CGM devices provide real-time glucose readings and trend analysis, enabling more precise and proactive disease management compared to traditional monitoring methods. This shift is particularly evident among urban patients and those requiring intensive insulin therapy, where continuous monitoring supports better glycemic control. The growing availability of technologically advanced and user-friendly CGM solutions is further improving patient compliance and engagement. As awareness and accessibility improve, CGM is expected to play a larger role in both diagnosis and long-term diabetes management across India.

Expansion of Combination Drug Therapies Improving Treatment Outcomes

The increasing use of combination drug therapies is shaping treatment approaches within the Indian diabetes therapeutics segment. These therapies integrate multiple mechanisms of action, allowing for more effective blood glucose control, particularly in patients with Type 2 diabetes who require multi-drug regimens. The shift toward fixed-dose combinations is also simplifying treatment protocols, reducing pill burden, and improving patient adherence. Pharmaceutical companies are actively expanding their portfolios in this segment to address diverse patient needs and disease progression stages. This trend is contributing to more personalized and efficient treatment strategies, supporting sustained growth in the therapeutics market.

Market Segmentation

• Based on the disease type, the market is segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and prediabetes.
• Based on the diagnosis, the market is segmented into blood glucose monitoring, and continuous glucose monitoring.
• Based on the therapeutics, the market is segmented into insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs.

Type 2 Diabetes Segment Dominates Due to Expanding Patient Base and Long-Term Treatment Demand

The Type 2 diabetes segment represents the largest share within the Indian diabetes diagnosis and treatment market, primarily driven by its high and continuously increasing prevalence. Lifestyle-related factors such as reduced physical activity, dietary changes, and rising obesity levels are significantly contributing to the growing patient population. This has led to sustained demand for both diagnostic solutions like BGM and CGM, as well as therapeutics, including oral anti-diabetic drugs and insulin. The chronic nature of Type 2 diabetes further necessitates continuous monitoring and long-term treatment, reinforcing recurring market demand. As early diagnosis rates improve, the segment continues to drive overall market expansion.

Continuous Glucose Monitoring (CGM) Segment Expands with Shift Toward Real-Time Diabetes Management

The CGM segment is witnessing strong growth within the diagnosis category of the Indian diabetes diagnosis and treatment market, supported by increasing preference for real-time glucose tracking. Unlike traditional monitoring methods, CGM systems provide continuous data, enabling better glycemic control and timely therapeutic decisions. This is particularly beneficial for insulin-dependent patients and those requiring intensive disease management. The growing availability of advanced CGM devices and rising awareness among patients and healthcare providers are accelerating adoption. As the market shifts toward more precise and technology-driven care, CGM is emerging as a key growth driver within the diagnosis segment.

Market Players Outlook

The major companies operating in the India diabetes diagnosis and treatment market include Abbott India Limited, Becton Dickinson India Private Limited, Medtronic Private Limited, Novo Nordisk India Private Limited, Sanofi India Limited, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In August 2025, Abbott launched the next-gen FreeStyle Libre 2 Plus CGM device in India, providing real-time glucose data every minute with optional high/low sugar alerts. The sensor transmits data directly to smartphones without manual scans and lasts up to 15 days. It integrates with Abbott’s digital health platforms, enabling remote monitoring by caregivers and healthcare professionals.
• In February 2026, Abbott and Novo Nordisk India partnered to commercialize Extensior®, a GLP-1 receptor agonist for type 2 diabetes, in India. Extensior®, a second brand of Ozempic®, offers significant HbA1c reduction, weight loss, and cardiovascular and kidney risk reduction. Leveraging Novo Nordisk’s scientific expertise and Abbott’s distribution network, this collaboration aims to expand access to this evidence-based therapy beyond Novo Nordisk’s current regions.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the India diabetes diagnosis and treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.